Press Releases

• • All Categories
  • C. difficile
  • Chikungunya
  • COVID-19
  • DUKORAL®
  • IXIARO®
  • Lyme Disease
  • Uncategorized

Filter By Year 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

July 15, 2008

VIVALIS AND INTERVET SCHERING PLOUGH ANIMAL HEALTH SIGN A LETTER OF INTENT FOR A COMMERCIAL LICENSE TO USE EBx® CELL LINE FOR A VIRAL VACCINE PRODUCTION

July 8, 2008

VIVALIS GRANTS RESEARCH LICENCE TO ACAMBIS TO EVALUATE EB66® CELL LINE FOR VIRAL VACCINES PRODUCTION

June 30, 2008

A MAJOR STEP TAKEN IN THE DEVELOPMENT OF VIVALIS: FILING OF THE EB66® CELL LINE BMF WITH THE AMERICAN FDA CONFIRMATION OF BREAKTHROUGH TECHNOLOGY STATUS FOR THE PRODUCTION OF VACCINES AND PROTEINS

June 18, 2008

VIVALIS GRANTS RIGHTS TO EBx® CELL LINE FOR TESTING IN PRODUCTION OF VIRAL VACCINES

June 3, 2008

FOLLOWING POSITIVE RESULTS VIVALIS AND BAVARIAN NORDIC EXTEND THE EBx® RESEARCH LICENCE

May 20, 2008

SOCIETE GENERALE INITIATES VIVALIS COVERAGE WITH A “BUY” RECOMMENDATION AND A PRICE TARGET OF €8.10

April 30, 2008

VIVALIS ANNOUNCES THE FILING OF ITS FIRST ANNUAL REGISTRATION DOCUMENT

April 16, 2008

Quarterly report: 1st Quarter 2008 Cash position of € 22, 8 million Objectives for 2008: Signing of 7 to 9 new EBx® licenses, including 2 commercial licenses

April 14, 2008

VIVALIS WILL PARTICIPATE IN THE SMALL CAP EVENT IN PARIS ON APRIL 21 AND 22, 2008

April 1, 2008

VIRBAC EXERCISES ITS OPTION FOR A COMMERCIAL LICENCE AGREEMENT TO USE VIVALIS’ EBx® PLATFORM FOR THE PRODUCTION OF SEVERAL VACCINES.